Stockreport

Cullgen Begins Phase 1 Dosing of its Potential First-in-Class, Oral Pan-TRK Protein Degrader for Acute and Chronic Pain

Pulmatrix, Inc.  (PULM) 
Last pulmatrix, inc. earnings: 8/5 09:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.pulmatrix.com
PDF SAN DIEGO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Cullgen Inc. (“Cullgen”), a privately-held, clinical-stage biopharmaceutical company applying its proprietary targeted pro [Read more]